About Us
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care.
Management Team
Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/ capital market experience in the biotech sector. Since 2018, Ms. Toledano served as a Member of the Board, Chair of the Audit Committee, and Member of the Compensation and Scientific Advisory Committee at Entera, and as CEO since July 2022. Previously, Miranda served as COO and CFO, and Director of TRIGR Therapeutics, a private oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX 3 years after the Company’s founding. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX). Ms. Toledano is also a Director at Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL).
Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
Rachel B Wagman, MD, FACE, FACP, serves as key clinical advisor to Entera. Dr. Wagman brings more than 20 years of metabolic bone disease and women’s health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management. Dr. Wagman’s clinical leadership experiences include progressive roles at Eli Lilly, Amgen, and Myovant Sciences, where as Senior Vice President Clinical Development, she integrated Myovant’s development portfolio into the newly-established Sumitomo Pharma America.
She completed her BA at the University of Pennsylvania, MD at Jefferson Medical College, Internal Medicine residency at Thomas Jefferson University Hospital, and postdoctoral fellowship in Endocrinology, Gerontology, and Metabolism at Stanford University School of Medicine. She is a Fellow of both the American College of Endocrinology and the American College of Physicians and holds dual board certifications in Internal Medicine and Endocrinology, Diabetes, and Metabolism.
Dr. Felicia Cosman is a clinical scientist, endocrinologist and osteoporosis specialist. She is Professor of Medicine at Columbia University and has been North American Co-Editor in Chief of the journal Osteoporosis International since 2016. She received a BA from Cornell, MD from Stony Brook Medical School, and completed internship, residency and endocrinology fellowship at Columbia University College of Physicians and Surgeons. Throughout her career, Dr. Cosman has had many grants from the National Institutes of Health, the Department of Defense, multiple foundations and industry. She has published over 190 peer-reviewed papers and over 50 book chapters and has been an Associate Editor for several osteoporosis textbooks, most recently the Fifth Edition of Marcus and Feldman’s Osteoporosis.
Dr. Cosman has been involved in many studies evaluating multiple therapeutic agents for osteoporosis. The main focus of her research has been the use of anabolic medications and treatment sequencing. Dr. Cosman has investigated the effect of teriparatide on biochemical and densitometric outcomes, bone microarchitecture and strength, and cellular action using bone biopsy. She performed a series of studies that investigated cyclic, combination and sequential regimens of teriparatide with antiresorptives, including bisphosphonates, denosumab, raloxifene and estrogen. She led a novel study evaluating the effect of teriparatide on bone formation in the human femur in patients undergoing hip arthroplasty. Dr. Cosman has also been a primary investigator on many studies evaluating the efficacy of abaloparatide and romosozumab treatment for osteoporosis. She is well known for work on optimizing anabolic treatment regimens, longterm treatment strategies in postmenopausal women, and implementing therapeutic goals for osteoporosis management.
She received the ACE Distinction in Endocrinology Award in 2019 and the ASBMR Bartter Award for clinical research in September 2020.
Steven R. Goldstein, MD is on the Faculty of the Department of Obstetrics and Gynecology at New York University Grossman School of Medicine, as a Professor of Obstetrics and Gynecology. He is the immediate past President of the International Menopause Society. He is past President and Fellow of the American Institute of Ultrasound in Medicine. He is a past President of the North American Menopause Society (NAMS).
Dr. Goldstein has authored the International Menopause Society’s white paper on bone health. He has published seven books on women’s health topics, including menopause, perimenopause early pregnancy monitoring, abnormal uterine bleeding and gynecologic ultrasound. He has authored more than 60 chapters as well as over 140 original research articles. He is a past Chairman of the American College of Obstetrics and Gynecology, New York Section. He has been a guest faculty member, invited speaker, visiting professor or course director over 400 times throughout the United States and the world.
Dr. Goldstein is an Honorary Fellow of the Royal College of Obstetricians and Gynaecologists. He has received numerous awards such as the William J. Fry Memorial Lecture Award from the American Institute of Ultrasound in Medicine (AIUM) in 2023, the Ian Donald Gold Medal from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) in 2023, the Holmes Pioneer Award from AIUM in 2019, and the Clarkson Award from NAMS in 2016.
Dr. Burshtein leads Research and Development at Entera since joining the Company in 2012, as Director of Pharmaceutical R&D. Dr. Burshtein holds over 20 years of experience in the field of drug delivery, pharmacology and biopharmaceutics, with a primary focus on the challenging area of oral delivery of therapeutic peptides. Gregory is the inventor of many patents and has presented and authored multiple publications in peer-reviewed journals related to oral delivery of peptides.
Dr. Burshtein obtained his Ph.D. in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of the Hebrew University of Jerusalem.
Dr. Hillel Galitzer has served as our Chief Operating Officer since February 2014, prior to which he served as our Director of Scientific Development from July 2012. Dr. Galitzer has more than ten years of experience in medical research and molecular biology. Between August 2010 and February 2014, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of Optivasive Inc. He has written numerous publications in peer-reviewed journals and has lectured and presented in international conferences and universities.
Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.
Dana Yaacov-Garbeli has served as our Israel-based Chief Financial Officer since June 2019 and as the Company’s Chief Financial Officer effective as of July 15, 2022. Ms. Yaacov-Garbeli has over 15 years of chief finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She is an expert in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli is also a partner at A2Z-Finance, a company that provides financial and accounting services.
Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.
Ms. Hoppe leads clinical operations at Entera since 2018. Ms. Hope has over 30 years of clinical operations experience in major international pharmaceutical and biopharmaceutical companies and various clinical research organizations. Her experience ranges from serving as clinical research associate (Sanofi for 9 years) to project management lead at several of the leading CROs and Vertex Pharmaceuticals.
Scientific Advisory Board
Vice-Chair, Department of Medicine for International Research and Education; Chief, Emeritus, of the Division of Endocrinology; Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center.
Professor of Endocrinology, FIRMO Foundation, Florence, Italy.
Professor of Medicine and Consultant, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic.
Professor of Medicine, Emerita, Columbia University College of Physicians and Surgeons, Division of Endocrinology; Co-Editor in Chief of the journal Osteoporosis International.
Emeritus Professor of Internal Medicine and Executive Director of the San Francisco Coordinating Center, CPMC Research Institute, Department of Epidemiology and Biostatistics, University of California, San Francisco, US
Professor of medicine, Head of the Clinical Service and Research Laboratory of Bone Diseases, Vice-Dean for translational research and innovation at the Geneva Faculty of Medicine and University Hospital, Switzerland
Professor of Medicine and Deputy Head of Norwich Medical School at the University of East Anglia and Consultant in Metabolic Medicine at the Norfolk and Norwich University Hospital, UK.
Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society.
Vice President of the Israeli Foundation for Osteoporosis and Bone Diseases (IFOB), Endocrine Clinic Elisha Hospital; prior Head of Bone and Mineral Metabolism Unit, Rambam Health Care Campus, Haifa Israel.
Clinical Professor, Department of Intestinal Failure and Liver Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Clinical Professor, Department of Clinical Medicine, Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark
Director, Emeritus, Oregon Osteoporosis Center Portland, OR, United States
Emeritus Professor in Diseases of Bone & Mineral Metabolism, Advisor Center for Bone Quality, Leiden University Medical Center, The Netherlands.
Fellow of both the American College of Endocrinology and the American College of Physicians and holds dual board certifications in Internal Medicine and Endocrinology, Diabetes, and Metabolism.
Board of Directors
Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/ capital market experience in the biotech sector. Since 2018, Ms. Toledano served as a Member of the Board, Chair of the Audit Committee, and Member of the Compensation and Scientific Advisory Committee at Entera, and as CEO since July 2022. Previously, Miranda served as COO and CFO, and Director of TRIGR Therapeutics, a private oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX 3 years after the Company’s founding. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX). Ms. Toledano is also a Director at Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL).
Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
Gerald Lieberman has served as a member of our Board since April 2014 and became our Chairman in July 2019. Mr. Lieberman is also a member of the board of directors of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals and the world’s largest generic drug developer and manufacturer, where he chairs the Audit Committee and serves on both the Human Resources and Compensation Committee and the Finance Committee. He also serves as Chairman of the Board of Directors of DosenRx, Ltd., a Digital health company that has developed a personalized, patient-controlled device for delivering medication. He is also currently a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at Alliance Bernstein L.P., where he served as President and Chief Operating Officer from 2004 to 2009, as Chief Operating Officer from 2003 to 2004 and as Executive Vice President, Finance and Operations from 2000 to 2003. From 1998 to 2000, he served as Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc., until it was acquired by Alliance Capital in 2000, forming Alliance Bernstein L.P. Prior to that, he served in various executive positions at Fidelity Investments and at Citicorp. Prior to joining Citicorp he was a certified public accountant with Arthur Andersen. He previously served on the board of directors of Forest Laboratories, LLC from 2011 to 2014, Computershare Ltd. from 2010 to 2012 and Alliance Bernstein L.P. from 2004 to 2009.
Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business from the University of Connecticut.
Sean Ellis has served as a member of our Board since June 2019. Mr. Ellis brings extensive knowledge of both life sciences and the U.S. financial markets, with a longstanding history in asset management. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and related healthcare industries. Centillion is one of Entera Bio’s earliest investors and largest shareholders.
He holds a BA from New York University and MBA from Columbia University.
Ms. Taitel has over 30 years of global C-level biopharma commercial and strategic executive experience. Ms. Taitel currently serves as the Head of Sanofi’s Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock®, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led Kadmon Board’s Executive Commercial Committee. Beginning in 1997, Ms. Taitel had held various commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women’s healthcare.
Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.
Gerald M. Ostrov has served as a member of our Board since January 2019. Mr. Ostrov consults and invests in new technologies in the medical device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including Mother’s Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo, a developer of next generation baby and mother health monitoring for both hospital and home use. From 2008 to 2010, he served as Chairman and CEO of Bausch & Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch & Lomb following its going-private transaction. From 1998 until 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson & Johnson’s Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson & Johnson and quickly rose to serve as Company Group Chairman of the Consumer and Personal Care businesses in North America. From 1982 to 1991, he served as President of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson & Johnson. From 1973 to 1976, Mr. Ostrov worked at Procter & Gamble.
Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard.
Yonatan Malca has served as a member of our Board since 2011. Mr. Malca currently serves as a Chief Executive Officer and director of NanoGohst Ltd. Since 2010 until 2021, he served as a Chief Executive Officer and director of D.N.A Biomedical Mr. Malca also serves as a director of Nextgen-Biomed LTD. (TASE:NXGN) and Jungo Connectivity Ltd. (TASE:JNGO) , each of which is an Israeli public company.
Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel.
